Globus Medical (NYSE:GMED) Posts Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Globus Medical (NYSE:GMED) issued its earnings results on Thursday. The medical device company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.92 by $0.20, FiscalAI reports. The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.69%. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.68 EPS. Globus Medical updated its FY 2026 guidance to 4.700-4.800 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Q1 results$4.70–$4.80 while reaffirming revenue guidance of $3.18–$3.22 billion.
• Base business strength
• Enabling Technologies shift
• Product innovation
• Nevro integration risk

Globus Medical Stock Performance

Shares of NYSE:GMED traded down $7.26 during trading on Friday, reaching $77.81. The stock had a trading volume of 6,038,415 shares, compared to its average volume of 1,076,670. The firm’s fifty day moving average is $89.86 and its 200 day moving average is $86.65. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40. The stock has a market cap of $10.52 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 1.82 and a beta of 1.00.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GMED shares. Canaccord Genuity Group lifted their price target on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a report on Friday, January 9th. Barclays lifted their price target on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Royal Bank Of Canada lifted their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday. Wells Fargo & Company decreased their price target on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average price target of $106.36.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

Insiders Place Their Bets

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. boosted its stake in Globus Medical by 1,235.2% during the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after acquiring an additional 3,595,339 shares in the last quarter. Bank of Montreal Can boosted its stake in Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after acquiring an additional 3,351,380 shares in the last quarter. Sculptor Capital LP boosted its stake in Globus Medical by 31.9% during the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock worth $162,936,000 after acquiring an additional 667,850 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Globus Medical by 1,303.9% during the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after acquiring an additional 1,908,795 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Globus Medical by 72.1% during the third quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock worth $115,166,000 after acquiring an additional 842,547 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

Featured Stories

• Five stocks we like better than Globus Medical
• Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
• Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
• Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
• Water Infrastructure: Why This Boring Sector Could Get Exciting